Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Google Inc (GOOG) vs Heron Therapeutics Inc (HRTX) Price & Performance

Google IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Google Inc vs Heron Therapeutics Inc — how do they compare? Google Inc trades at $371.28 (market cap $4.52T), while Heron Therapeutics Inc trades at $0.49 (market cap $84.50M). The key difference: Google Inc is far larger — about 53491.1× Heron Therapeutics Inc's market cap, and Google Inc pays a 0.24% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

GOOGHRTX
Market Cap
$4.52T$84.50M
Volume
1,511,127
Sector
TechnologyHealth
52-Week High
$399.06$2.02
52-Week Low
$183.77$0.39
Enterprise Value
$4.49T$182.40M
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $370.43, up 3.67% on the day, with strong bullish momentum from recent earnings beats and a consensus analyst price target of $457.50. The stock shows robust fundamentals with 2025 revenue of $402.84B, net income margin of 37.92%, and consistent cash flow growth. Technical indicators are bullish, with the current price near resistance at $374, while sentiment is positive due to Warren Buffett's recent endorsement and AI-driven growth prospects.

Outlook remains favorable with earnings growth and AI expansion as key catalysts, though regulatory risks and market volatility pose challenges. The stock offers upside potential aligned with analyst targets, supported by high institutional ownership and strong profitability metrics.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, up 13.93% today, showing volatile momentum amid mixed technical signals. The company maintains strong gross margins of 71.12% but struggles with profitability, posting a net loss of $20.20 million in 2025. Recent Q1 2026 earnings missed expectations with a $0.04 loss per share, though management reaffirmed full-year guidance. Analyst consensus remains overwhelmingly bullish with 94.74% buy ratings, contrasting with a recent Zacks Strong Sell designation.

HRTX presents a high-risk opportunity with significant analyst support but persistent financial challenges. The bullish sentiment stems from potential patent developments and commercial execution, while risks include ongoing losses, competitive pressures, and the discrepancy between analyst optimism and recent negative ratings. The stock's current valuation at 0.49x sales appears reasonable if the company can achieve profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX